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The PD-1/PD-L1 blockade is now recognized as one of the
basic immune interventions for development of combina-
tion cancer immunotherapy. We have been screening che-
mical libraries to obtain compounds which have an
activity to augment anti-tumor activity of the PD-1/PD-L1
blockade. We have previously shown that activation of
NF-kB and STAT3 signals in both cancer cells and
immune cells plays important roles in cancer cell-induced
immunosuppression, and their inhibition may augment
anti-tumor CTL. Curcumin, a major active component of
turmeric, has activities to inhibit both NF-kB and STAT3
signals. We have recently developed a highly absorptive
form of curcumin which oral administration resulted in
high plasma concentration. In this study, we evaluated
combination treatment of this highly absorptive form of
curcumin with the PD-1/PD-L1 blockade. Curcumin
inhibited significantly in vitro production of IL6 and IL8
by human ovarian cancer cell lines (OC) having activated
NF-kB and STAT3 signaling. In nude mice implanted
with human OC, T-cell stimulatory activity of murine DC
was impaired partly through increased human IL-6 from
human OC. Systemic p.o. administration of curcumin
decreased human IL6 in mouse serum and restored T-cell
stimulatory activity of murine DC in spleens and tumors.
In two syngeneic murine colon cancer models, NF-kB
dependent IL6 producing MC38 in B6 mice and NF-kB
non-activated IL6 non-producing CT26 in Balb/C mice,
curcumin p.o. administration resulted in the significant
augmentation of tumor antigen-specific CD8+ T-cell
induction accompanied by increased T-cell stimulatory
activity of DC via decreased STAT3 and NF-kB signaling,
although curcumin did not inhibit proliferation of both
tumor cell lines. Furthermore, p.o. administration of
curcumin into non-tumor bearing B6 mice immunized
with ovalbumin (OVA) peptide augmented OVA-specific
CTL induction. These results indicate that curcumin not
only enhances tumor antigen specific T-cell via reversal of
tumor-induced immunosuppression (e.g. IL6 induced DC
impairment), but also enhances CTL via directly acting
on immune cells. Since PD-1 positive T cells were infil-
trated in tumors expressing PD-L1, we evaluated combi-
nation of curcumin and anti-PD-L1 blockade, and found
that combination of curcumin and anti-PD-L1 Ab had
synergistic anti-tumor activity. These results indicate that
combination of curcumin which enhances induction of
tumor antigen specific, PD-1 positive CTL in tumors
via acting on both cancer cells and immune cells and
local PD-1/PD-L1 blockade, is an attractive strategy for
development of effective cancer immunotherapy.
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